Exercise: A Non-Pharmaceutical “Drug” To Reduce Heart Disease in Breast Cancer Patients

MedicalResearch.com Interview with:

Christina M. Dieli-Conwright, PhD, MPH, FACSM, CSCSAssistant Professor of ResearchDirector, Integrative Center for Oncology Research in ExerciseDivision of Biokinesiology & Physical Therapy, Ostrow School of DentistryDepartment of Medicine, Keck School of MedicineUniversity of Southern CaliforniaLos Angeles, CA 90033

Dr. Dieli-Conwright

Christina M. Dieli-Conwright, PhD, MPH, FACSM, CSCS
Assistant Professor of Research
Director, Integrative Center for Oncology Research in Exercise
Division of Biokinesiology & Physical Therapy, Ostrow School of Dentistry
Department of Medicine, Keck School of Medicine
University of Southern California
Los Angeles, CA 90033 

MedicalResearch.com: What is the background for this study? What are the main findings? 

Response: This study was designed to assess the effects of an aerobic and resistance exercise on metabolic dysregulation in sedentary, obese breast cancer survivors, however we further examined the effects on cardiovascular disease risk measured by the Framingham Risk Score, reported here.

Our findings indicated that exercise, indeed, reduces the risk of cardiovascular disease in this population.  Continue reading

Breast Cancer Survivors More Likely To Develop Subsequent Blood Cancers

MedicalResearch.com Interview with:
medicalresearch.comDr. Marie Joelle Jabagi, PharmD, MPH

University of Paris Sud, Paris-Saclay University, Paris
Health Product Epidemiology Department
French National Agency for Medicines and Health Products Safety
Saint-Denis, France

MedicalResearch.com: What is the background for this study?

Response: Secondary hematologic malignant neoplasms that develop months or years after the diagnosis of breast cancer may be a consequence of genetic predisposition, environmental factors, previous cancer treatments or a combination of all those factors. These secondary malignant neoplasms are increasingly becoming a concern given that the population of breast cancer survivors is growing substantially. However, their frequency in real life has been poorly investigated to date.

The aims of our research were to estimate the frequency of various types of hematologic malignant neoplasm following a diagnosis of primary breast cancer among women aged 20 to 85 years in France during the past decade, and to compare it to the corresponding frequency in women of the French general population.

Continue reading

Young Survivors of Cancer at Increased Risk of Endocrine Disease

MedicalResearch.com Interview with:
“Cancer awareness” by Susan Roberts is licensed under CC BY 2.0Mette Vestergaard Jensen, MD

Danish Cancer Society Research Center

MedicalResearch.com: What is the background for this study?

Response: Cancer survival rates have improved and it is necessary to explore the long-term consequences of cancer treatment. Adolescents and young adults with cancer are at risk for several therapy-related late effects; however, these have not been studied extensively. We investigatet the lifetime risks of endocrine late effects of cancer and cancer treatment in adolescent and young adult cancer s

Continue reading

Cancer Survivors: Discussions of Survivorship Have Room For Improvement

Danielle Blanch Hartigan, PhD, MPH Cancer Prevention Fellow National Cancer InstituteMedicalResearch.com Interview with:
Danielle Blanch Hartigan, PhD, MPH
Cancer Prevention Fellow
National Cancer Institute
MedicalResearch.com: What are the main findings of the study?

Dr. Blanch-Hartigan: Results from this nationally-representative survey of oncologists and PCPs suggest that discussion of survivorship care planning with cancer survivors does not always occur. Training and knowledge specific to survivorship care and coordinated care between PCPs and oncologists were associated with increased survivorship discussions with survivors.

Continue reading

Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care

Janet S. de Moor, PhD, MPH  Program Director, Office of Cancer Survivorship Division of Cancer Control and Population Sciences National Cancer Institute/National Institutes of Health Bethesda, MD 20891-8336MedicalResearch.com Interview with Janet S. de Moor, PhD, MPH

Program Director, Office of Cancer Survivorship
Division of Cancer Control and Population Sciences
National Cancer Institute/National Institutes of Health
Bethesda, MD 20891-8336

MedicalResearch.com: What are the main findings of the study? 

Dr. de Moor: The number of people who have been diagnosed with cancer during their lifetime has been steadily increasing.  As of January 1, 2012, approximately 13.7 million cancer survivors were living in the United States with projected prevalence to approach 18 million by 2022.  Women with breast cancer and men with prostate cancer represent the two largest groups of cancer survivors, accounting for 22% and 20% of the population respectively.  Sixty-four percent of cancer survivors have survived 5 years or more; 40% have survived 10 years or more; and 15% have survived 20 years or more after diagnosis.  Over the next decade, the number of people who have lived 5 years or more after their cancer diagnosis is projected to increase approximately 37% to 11.9 million.
Continue reading